Table 1.
SUVmax among different groups of 108 patients with gastroenteropancreatic neuroendocrine tumors on SSA monotherapy
| Baseline characteristics | Patients, n | Mean SUVmax ± SD | p value a | Effect size b (95% CI) |
|---|---|---|---|---|
| Gender | ||||
| Male | 81 | 57.9 ± 39.5 | .56 | |
| Female | 27 | 55.0 ± 40.5 | ||
| Age, years | ||||
| ≤50 | 20 | 63.8 ± 45.1 | .72 | |
| <50 and ≤60 | 38 | 56.0 ± 39.2 | ||
| <60 and ≤70 | 32 | 53.2 ± 39.2 | ||
| >70 | 18 | 53.7 ± 38.8 | ||
| Tumor site | ||||
| Gastrointestinal tract | 81 | 45.8 ± 28.4 | <.001 | 72.1% (57.1–88.4%) |
| Pancreas | 27 | 87.6 ± 52.0 | ||
| Tumor grade | ||||
| 1 | 53 | 57.7 ± 38.2 | .36 | |
| 2 | 46 | 56.1 ± 44.3 | ||
| Ki67 index | ||||
| ≤5% | 61 | 52.8 ± 35.6 | .97 | |
| >5% | 26 | 59.8 ± 49.2 | ||
| Mitotic count | ||||
| <2 per 10 HPFs | 55 | 55.5 ± 39.8 | .58 | |
| ≥2 per 10 HPFs | 22 | 59.9 ± 39.0 | ||
| Germline mutation | ||||
| Yes | 9 | 53.5 ± 36.9 | .89 | |
| No | 99 | 56.5 ± 40.3 | ||
| Functioning tumor | ||||
| Yes | 49 | 62.7 ± 31.7 | .16 | |
| No | 59 | 48.5 ± 44.9 | ||
| Chromogranin A | ||||
| Normal (≤95 ng/mL) | 34 | 63.0 ± 46.0 | .87 | |
| Elevated (>95 ng/mL) | 71 | 53.4 ± 37.0 | ||
| Urine 5‐HIAA | ||||
| Normal (≤15 mg/day) | 39 | 53.6 ± 38.2 | .24 | |
| Elevated (>15 mg/day) | 20 | 40.8 ± 20.8 | ||
| SSA naïve | ||||
| Yes | 30 | 53.0 ± 36.1 | .69 | |
| No | 78 | 57.5 ± 41.4 |
a
Comparisons among groups were made using one‐way analysis of variance (ANOVA) on log‐transformed SUVmax data.
b
Effect size was estimated by taking antilog transformations of the ANOVA results.
Abbreviations: 5‐HIAA, 5‐hydroxyinidoleacetic acid; CI, confidence interval; HPF, high‐power field; SSA, somatostatin analog; SUVmax, maximum standardized uptake value.